PPPs and innovation Opportunities and challenges within a European public-public partnership

M. I. Esveld, Ministerie van VWS – 24 september Goals Development of new drugs, vaccines and diagnostics HIV, TB and Malaria Capacity building in Africa for research

M. I. Esveld, Ministerie van VWS – 24 september Public-public Co-funding MS and EC Current programme: … mln+200 mln 14 Members EEIG Secretariat in NL Art 185

Scope Phase II/III Networks of Excellence Training on ethics, (financial) management Clinical trials registry Governance General Assembly Steering Committee Executive Secretriat Strategic Advisory Committee 4 M. I. Esveld, Ministerie van VWS – 24 september 2013

Why a PPP? Market failure Limited capacity in Sub-sahara Africa You can not perform clinical tests in Europe Economy of scale What about the private sector? Under EDCTP1: high ambitions, little results Training provided by EFPIA members Product development partnerships seen as competitors Under EDCTP2?? 5 M. I. Esveld, Ministerie van VWS – 24 september 2013

6 Issues Membership Participation of new MS and African partners Governance Participation of African partners Participation of non-KP7 members Participation of private sector Balance of power M. I. Esveld, Ministerie van VWS – 24 september 2013

7 Issues - continued Scope Other Neglected Tropical Diseases Other phases (I/IV) and Health Systems Other regions (Asia, Latin America) Funding Total budget Cash versus ‘in kind’ Common pot or earmarking Contribution ‘poor countries’ M. I. Esveld, Ministerie van VWS – 24 september 2013

Questions?